Prostate Cancer Theranostics
Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used for the diagnosis (i.e., staging and restaging) and treatment of patients with prostate cancer. Radionuclide PSMA therapy is a useful new treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) and potentially also in patients with hormone-sensitive prostate cancer. The course will cover the spectrum of […]
€950